Cryptic KMT2A::MLLT10 Rearrangement in a Highly Aggressive Acute Myeloid Leukemia
Corresponding Author
Gerasimos Tsilimidos
Hematology Service and Central Laboratory of Hematology, University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
Correspondence:
Gerasimos Tsilimidos ([email protected])
Search for more papers by this authorIlaria Scarpelli
Oncogenomic Laboratory, Hematology Service, University Hospital and University of Lausanne, Lausanne, Switzerland
Search for more papers by this authorFrançoise Solly
Hematology Service and Central Laboratory of Hematology, University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
Search for more papers by this authorMarine Gossin
Hematology Service and Central Laboratory of Hematology, University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
Search for more papers by this authorAmandine Segot
Hematology Service and Central Laboratory of Hematology, University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
Search for more papers by this authorJacqueline Pouw Schoumans
Oncogenomic Laboratory, Hematology Service, University Hospital and University of Lausanne, Lausanne, Switzerland
Search for more papers by this authorSabine Blum
Hematology Service and Central Laboratory of Hematology, University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
Search for more papers by this authorCorresponding Author
Gerasimos Tsilimidos
Hematology Service and Central Laboratory of Hematology, University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
Correspondence:
Gerasimos Tsilimidos ([email protected])
Search for more papers by this authorIlaria Scarpelli
Oncogenomic Laboratory, Hematology Service, University Hospital and University of Lausanne, Lausanne, Switzerland
Search for more papers by this authorFrançoise Solly
Hematology Service and Central Laboratory of Hematology, University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
Search for more papers by this authorMarine Gossin
Hematology Service and Central Laboratory of Hematology, University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
Search for more papers by this authorAmandine Segot
Hematology Service and Central Laboratory of Hematology, University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
Search for more papers by this authorJacqueline Pouw Schoumans
Oncogenomic Laboratory, Hematology Service, University Hospital and University of Lausanne, Lausanne, Switzerland
Search for more papers by this authorSabine Blum
Hematology Service and Central Laboratory of Hematology, University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
Search for more papers by this authorFunding: The authors received no specific funding for this work.
Gerasimos Tsilimidos and Ilaria Scarpelli contributed equally.
Open Research
Data Availability Statement
The authors have nothing to report.
References
- 1 Y. Kim, B. Kim, M. W. Seong, et al., “Cryptic KMT2A/MLLT10 Fusion Detected by Next-Generation Sequencing in a Case of Pediatric Acute Megakaryoblastic Leukemia,” Cancer Genetics 276-277 (2023): 36–39, https://doi.org/10.1016/j.cancergen.2023.07.003.
- 2 H. Van Limbergen, B. Poppe, A. Janssens, et al., “Molecular Cytogenetic Analysis of 10;11 Rearrangements in Acute Myeloid Leukemia,” Leukemia 16, no. 3 (2002): 344–351, https://doi.org/10.1038/sj.leu.2402397.
- 3 H. Dohner, A. H. Wei, F. R. Appelbaum, et al., “Diagnosis and Management of AML in Adults: 2022 Recommendations From an International Expert Panel on Behalf of the ELN,” Blood 140, no. 12 (2022): 1345–1377, https://doi.org/10.1182/blood.2022016867.
- 4 C. Motllo, J. M. Ribera, M. Morgades, et al., “Frequency and Prognostic Significance of t(v;11q23)/KMT2A Rearrangements in Adult Patients With Acute Lymphoblastic Leukemia Treated With Risk-Adapted Protocols,” Leukemia & Lymphoma 58, no. 1 (2017): 145–152, https://doi.org/10.1080/10428194.2016.1177182.
- 5 D. A. Arber, A. Orazi, R. P. Hasserjian, et al., “International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating Morphologic, Clinical, and Genomic Data,” Blood 140, no. 11 (2022): 1200–1228, https://doi.org/10.1182/blood.2022015850.
- 6 P. Ruminy, V. Marchand, N. Buchbinder, et al., “Multiplexed Targeted Sequencing of Recurrent Fusion Genes in Acute Leukaemia,” Leukemia 30, no. 3 (2016): 757–760, https://doi.org/10.1038/leu.2015.177.
- 7 R. M. Stone, S. J. Mandrekar, B. L. Sanford, et al., “Midostaurin Plus Chemotherapy for Acute Myeloid Leukemia With a FLT3 Mutation,” New England Journal of Medicine 377, no. 5 (2017): 454–464, https://doi.org/10.1056/NEJMoa1614359.
- 8 J. D. Khoury, E. Solary, O. Abla, et al., “The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms,” Leukemia 36, no. 7 (Jul 2022): 1703–1719, https://doi.org/10.1038/s41375-022-01613-1.
- 9 P. R. Blackburn, J. B. Smadbeck, I. Znoyko, et al., “Cryptic and Atypical KMT2A-USP2 and KMT2A-USP8 Rearrangements Identified by Mate Pair Sequencing in Infant and Childhood Leukemia,” Genes, Chromosomes & Cancer 59, no. 7 (2020): 422–427, https://doi.org/10.1002/gcc.22842.
- 10 L. M. Hoffmeister, J. Suttorp, C. Walter, et al., “Panel-Based RNA Fusion Sequencing Improves Diagnostics of Pediatric Acute Myeloid Leukemia,” Leukemia 38, no. 3 (2024): 538–544, https://doi.org/10.1038/s41375-023-02102-9.
- 11 L. K. Schmalbrock, A. Dolnik, S. Cocciardi, et al., “Clonal Evolution of Acute Myeloid Leukemia With FLT3-ITD Mutation Under Treatment With Midostaurin,” Blood 137, no. 22 (2021): 3093–3104, https://doi.org/10.1182/blood.2020007626.
- 12 B. Jiang, Y. Zhao, Y. Luo, et al., “Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring KMT2A Rearrangement and Its Prognostic Factors,” Cell Transplant. Jan-Dec 33 (2024): 9636897231225821, https://doi.org/10.1177/09636897231225821.
